NCT04216134View on ClinicalTrials.gov

68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

December 9, 2022

Study Completion Date

December 9, 2022

Conditions
Biochemically Recurrent Prostate Carcinoma
Interventions
DRUG

Gallium Ga 68-labeled PSMA-11

Given IV

PROCEDURE

Positron Emission Tomography

Undergo 68GA-PSMA-11 PET

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT04216134 - 68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter